Progress in diagnosis and treatment of basal cell carcinoma by Liu, Yan et al.
11
Journal of Oncology Research | Volume 02 | Issue 01 | January 2020
Distributed under creative commons license 4.0 DOI: https://doi.org/10.30564/jor.v2i1.2038
Journal of Oncology Research
https://ojs.bilpublishing.com/index.php/jor
REVIEW
Progress in Diagnosis and Treatment of Basal Cell Carcinoma
Yan Liu   Mengxian Ren*   Youfei Zhao   Dong Liu   Fei Zhou
Anhui Taihe County People’s Hospital, Taihe, Anhui, 236600, China
ARTICLE INFO ABSTRACT
Article history
Received: 22 June 2020
Accepted: 22 June 2020
Published: 30 June 2020
Basal cell carcinoma is a common skin carcinogenesis that occurs in the 
epidermis and the basal layer of the skin.in general, basal cell carcinoma 
grows slowly, rarely metastasizes, but is locally invasive and destructive. 
The diagnosis is based on clinical manifestations, but the clinicopatho-
logical manifestations are different, and sometimes it is difficult to dif-
ferentiate from pigmented nevus, malignant melanoma, etc. Therefore, 
skin biopsy is essential for the diagnosis and assessment of the risk of 
recurrence.There are many ways to treat basal cell carcinoma. This article 
reviews the diagnosis and treatment.  
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1. Introduction
Basal cell carcinoma is a common skin cancer, often occurs on sun-exposed skin, common parts such as face, neck, hand, etc. Most basal cell 
carcinoma grow slowly, they are locally invasive and can 
destroy surrounding tissues [1]. The main causes of the 
disease are ultraviolet radiation, prolonged exposure to 
arsenic-contaminated water, food and drugs, or increased 
risk factors for human immunodeficiency virus infection 
and immunosuppression [2].
2. Diagnosis
The diagnosis of basal cell carcinoma depends on clinical 
manifestation, dermoscopy and histology. Dermoscopy 
will improve the diagnostic accuracy of skin lesions [3]. 
However, skin biopsy is essential for the diagnosis and 
assessment of the risk of recurrence. Histopathologically, 
basal cell carcinoma is usually composed of uniformly 
proliferating basal cell-like cells with dense nuclei, rela-
tively few cytoplasm and unclear boundaries [4]. In histo-
pathology, nodular lesions are formed by the proliferation 
of large basal cells, forming huge tumor nests, surrounded 
by palisades, with irregular central arrangement [5]. Histo-
pathologically, a sclerosing collagen stroma encapsulates 
a narrow cell chain and a small island of tumor cells. 
Fibroepithelial type usually occurs in the lower back, pre-
senting as skin color or erythema soft papules or pedicle 
papular nodular lesions similar to fibroma or papilloma [6].
3. Treatment
Surgical resection is the standard treatment for basal cell 
carcinoma. The study of surgical margin may realize 
complete resection of tumor at different anatomical lo-
cations. It is reported that the 5-year cure rate of 4-5 mm 
surgical margin is 9.95% [7]. Electro-drying and curettage 
is the removal of the surface of the tumor with a blade 
or a curettage device, and the burning of the remaining 
substrate with an electroacupuncture to control bleeding 
and destroy residual tumor cells. This method is simple but 
can not fully demonstrate that the tumor has been removed 
12
Journal of Oncology Research | Volume 02 | Issue 01 | January 2020
Distributed under creative commons license 4.0
and is more suitable for basal cell carcinoma located in low-
risk areas without invasive histopathological features [8]. 
cryosurgery liquid nitrogen acts directly on tumors, can 
form extracellular and intracellular ice crystals, destroy 
cell phospholipid membranes, and destroy peripheral tu-
mor-associated blood vessels for therapeutic purposes, but 
can not be histologically confirmed. cryosurgery can not 
be used as a first-line treatment for basal cell carcinoma, 
especially for tumors with a high risk of recurrence.topical 
imiquimod cream is an immune response regulator that 
induces cytokine production, stimulates cellular immu-
nity, and promotes apoptosis by bypassing anti-apoptotic 
mechanisms of tumor cells [9]. The curative effect is not 
as good as the local operation, the systemic side effect is 
many, usually uses in the low-risk position superficial bas-
al cell carcinoma treatment. Local fluorouracil by inhibit-
ing thymidine synthase interference DNA synthesis, local 
application of 5% FU cream has been proved to be gen-
erally effective, local fluorouracil is usually used only for 
superficial basal cell carcinoma in non-critical anatomical 
area, while for nodular or invasive basal cell carcinoma, 
it is generally forbidden [10]. light energy therapy, because 
reactive oxygen species produced by photosensitizers 
selectively absorb light induces cytotoxicity in tumor 
cells and local inflammatory responses that may lead to 
tumor destruction, complete tumor resection depends on 
the concentration of photosensitizers in tumor cells and 
the ability of light focusing in related regions.the effect of 
radiotherapy is positive, but recurrent basal cell carcino-
ma after radiotherapy may exhibit greater aggressiveness, 
including second recurrence and distant metastasis. in ad-
dition, the evidence of long-term efficacy of radiotherapy 
is limited. common side effects include chronic radiation 
dermatitis, permanent alopecia, dermal and subcutaneous 
fibrosis, necrosis, and secondary cutaneous malignancies. 
therefore, radiotherapy is generally applicable to patients 
not suitable for surgery, especially in high-risk areas [11].
4. Conclusion
To sum up, preclinical and pathological assessment of 
recurrence risk is necessary to select the best treatment 
strategy. According to the location of the tumor, the patho-
logical subtype, the patient’s condition, the beauty effect 
and the cost of treatment, different treatment methods can 
be used.
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